199 related articles for article (PubMed ID: 38732087)
1. Exposure of Bladder Cancer Cells to Blue Light (λ = 453 nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine.
Sturm S; Niegisch G; Windolf J; Suschek CV
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732087
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of human bladder carcinoma cell chemosensitivity to Mitomycin C through quasi-monochromatic blue light (λ = 453 ± 10 nm).
Hegmann L; Sturm S; Niegisch G; Windolf J; Suschek CV
J Photochem Photobiol B; 2022 Nov; 236():112582. PubMed ID: 36272336
[TBL] [Abstract][Full Text] [Related]
3. The effect of photochemical internalization of bleomycin in the treatment of urothelial carcinoma of the bladder: an in vitro study.
Arentsen HC; Falke J; Høgset A; Oosterwijk E; Alfred Witjes J
Urol Oncol; 2014 Jan; 32(1):49.e1-6. PubMed ID: 24140247
[TBL] [Abstract][Full Text] [Related]
4. Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines.
Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Palmeira C; Colaço A; Moreira da Silva V; Oliveira P; Lara Santos L
Urol Oncol; 2014 Jan; 32(1):41.e11-22. PubMed ID: 24035472
[TBL] [Abstract][Full Text] [Related]
5. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer.
Yang Y; Zhang LJ; Bai XG; Xu HJ; Jin ZL; Ding M
Biomed Pharmacother; 2018 Oct; 106():1307-1316. PubMed ID: 30119201
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin.
Krause S; Förster Y; Kraemer K; Fuessel S; Kotzsch M; Schmidt U; Wirth MP; Meye A; Schwenzer B
J Urol; 2005 Jul; 174(1):328-31. PubMed ID: 15947684
[TBL] [Abstract][Full Text] [Related]
8. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
[TBL] [Abstract][Full Text] [Related]
9. Capsaicin triggers autophagic cell survival which drives epithelial mesenchymal transition and chemoresistance in bladder cancer cells in an Hedgehog-dependent manner.
Amantini C; Morelli MB; Nabissi M; Cardinali C; Santoni M; Gismondi A; Santoni G
Oncotarget; 2016 Aug; 7(31):50180-50194. PubMed ID: 27367032
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
[TBL] [Abstract][Full Text] [Related]
11. Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms.
Ferro M; Giuberti G; Zappavigna S; Perdonà S; Facchini G; Sperlongano P; Porto S; Di Lorenzo G; Buonerba C; Abbruzzese A; Altieri V; Caraglia M
Oncol Rep; 2012 Feb; 27(2):409-15. PubMed ID: 22052369
[TBL] [Abstract][Full Text] [Related]
12. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
Mey V; Giovannetti E; De Braud F; Nannizzi S; Curigliano G; Verweij F; De Cobelli O; Pece S; Del Tacca M; Danesi R
Br J Cancer; 2006 Aug; 95(3):289-97. PubMed ID: 16868547
[TBL] [Abstract][Full Text] [Related]
13. Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines.
Pinto-Leite R; Arantes-Rodrigues R; Palmeira C; Gaivão I; Cardoso ML; Colaço A; Santos L; Oliveira P
J Toxicol Environ Health A; 2012; 75(13-15):788-99. PubMed ID: 22788366
[TBL] [Abstract][Full Text] [Related]
14. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study.
van der Heijden AG; Verhaegh G; Jansen CF; Schalken JA; Witjes JA
J Urol; 2005 Apr; 173(4):1375-80. PubMed ID: 15758808
[TBL] [Abstract][Full Text] [Related]
15. Decreased drug resistance of bladder cancer using phytochemicals treatment.
Cho CJ; Yu CP; Wu CL; Ho JY; Yang CW; Yu DS
Kaohsiung J Med Sci; 2021 Feb; 37(2):128-135. PubMed ID: 33280258
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
Pan J; Li X; Wu W; Xue M; Hou H; Zhai W; Chen W
Cancer Lett; 2016 Nov; 382(1):64-76. PubMed ID: 27591936
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer.
Seo HK; Ahn KO; Jung NR; Shin JS; Park WS; Lee KH; Lee SJ; Jeong KC
Oncotarget; 2014 Jan; 5(2):326-37. PubMed ID: 24504118
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells.
Zhang X; Taoka R; Liu D; Matsuoka Y; Tohi Y; Kakehi Y; Sugimoto M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921102
[TBL] [Abstract][Full Text] [Related]
19. Mitochondria as target to inhibit proliferation and induce apoptosis of cancer cells: the effects of doxycycline and gemcitabine.
Dijk SN; Protasoni M; Elpidorou M; Kroon AM; Taanman JW
Sci Rep; 2020 Mar; 10(1):4363. PubMed ID: 32152409
[TBL] [Abstract][Full Text] [Related]
20. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.
Messing EM; Tangen CM; Lerner SP; Sahasrabudhe DM; Koppie TM; Wood DP; Mack PC; Svatek RS; Evans CP; Hafez KS; Culkin DJ; Brand TC; Karsh LI; Holzbeierlein JM; Wilson SS; Wu G; Plets M; Vogelzang NJ; Thompson IM
JAMA; 2018 May; 319(18):1880-1888. PubMed ID: 29801011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
